



FEATURED OPTIONS RADAR REPORT



Smart Money Sees BioNTech as COVID Vaccine Winner

Ticker/Price: BNTX (\$92)

Analysis:

BioNTech SE (BNTX) a German Biotech company with shares +160% this year as it takes part in the recent for a COVID-19 vaccine that has shown positive early results, partnered with Pfizer (PFE). BNTX announced on 7/10 it expects its vaccine to be ready for approval by December and can product several hundred million doses before approval and 1 billion by the end of 2021. BNTX has caught the eye of institutional option traders with selling of 2000 December \$110 calls and 1000 December \$125 calls while buying 2000 March \$95 calls, 1000 March \$100 calls and 2000 March \$125 calls, positioning around an approval event. BNTX has recently made a parabolic move with other vaccine names seeing promising data and its rising 8 EMA been very supportive, currently at \$81.70 which aligns with a volume shelf, the first area to be a buyer followed by 21 MA and retest level at \$70.50. BNTX has decades of groundbreaking research in immunology, cutting-edge therapeutic platforms and a suite of patient profiling and bioinformatic tools to develop immunotherapies for cancer and other diseases. It leverages powerful new therapeutic mechanisms and exploit a diverse array of biological targets to harness the power of each patient's immune system to address the unique molecular signature of each patient's underlying disease. BNTX is uniquely positioned to develop and commercialize the next generation of immunotherapies with the potential to significantly improve clinical outcomes for patients and usher in a new era of individualized medicine. BNTX has a development pipeline of over 20 product candidates, of which 12 have entered into 13 ongoing clinical trials. Its most advanced programs are focused on oncology, where it has treated over 500 patients across 17 tumor types to date. BNTX's immunotherapy candidates span four distinct drug classes: mRNA Therapeutics, Cell Therapies, Antibodies, and Small Molecule Immunomodulators. Analysts have an average target of \$65 and short interest has risen to 3.28M shares into its rally. BAML recently upgraded to Buy with a \$105 target, seeing the COVID program having multiple key catalysts this year. Canaccord raised its target to \$97 on positive developments.

Hawk Vision:



Hawk's Perspective: BNTX has been the name most in my focus as quality and not as speculative as the MRNA/INO types, so definitely eyeing entry if pulls into those rising moving averages.

Confidence Ranking: \$\$